Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Syntara Limited ( (AU:SNT) ) has provided an update.
Syntara Limited has secured firm commitments to raise A$8 million via a two-tranche institutional placement and plans an additional A$2 million share purchase plan for eligible Australian and New Zealand shareholders, all priced at A$0.027 per share at a discount to recent trading levels. The capital injection, which extends Syntara’s cash runway to the third quarter of 2027, will fund five key clinical trial readouts in 2026, preparation for a Phase 2b myelofibrosis study of its lead drug amsulostat, enhancement of its global pan-LOX patent portfolio, and ongoing licensing discussions, potentially strengthening its competitive positioning and commercial prospects in hematology-focused drug development.
The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.19 price target. To see the full list of analyst forecasts on Syntara Limited stock, see the AU:SNT Stock Forecast page.
More about Syntara Limited
Syntara Limited (ASX:SNT) is a clinical-stage drug development company focused on advancing its pipeline of therapies, including lead asset amsulostat for myelofibrosis. The company is building a global pan-LOX patent suite to support multiple indications and is targeting value inflection through Phase 2b studies and associated licensing opportunities.
Average Trading Volume: 860,118
Technical Sentiment Signal: Sell
Current Market Cap: A$52.3M
For detailed information about SNT stock, go to TipRanks’ Stock Analysis page.